445 related articles for article (PubMed ID: 12584309)
1. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
Dey B; Del Castillo CS; Berger EA
J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
[TBL] [Abstract][Full Text] [Related]
2. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.
Lagenaur LA; Villarroel VA; Bundoc V; Dey B; Berger EA
Retrovirology; 2010 Feb; 7():11. PubMed ID: 20158904
[TBL] [Abstract][Full Text] [Related]
3. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
Zhang W; Godillot AP; Wyatt R; Sodroski J; Chaiken I
Biochemistry; 2001 Feb; 40(6):1662-70. PubMed ID: 11327825
[TBL] [Abstract][Full Text] [Related]
4. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.
Salzwedel K; Smith ED; Dey B; Berger EA
J Virol; 2000 Jan; 74(1):326-33. PubMed ID: 10590121
[TBL] [Abstract][Full Text] [Related]
5. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.
Liu L; Patel B; Ghanem MH; Bundoc V; Zheng Z; Morgan RA; Rosenberg SA; Dey B; Berger EA
J Virol; 2015 Jul; 89(13):6685-94. PubMed ID: 25878112
[TBL] [Abstract][Full Text] [Related]
6. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
7. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
9. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.
Chen W; Feng Y; Prabakaran P; Ying T; Wang Y; Sun J; Macedo CD; Zhu Z; He Y; Polonis VR; Dimitrov DS
J Virol; 2014 Jan; 88(2):1125-39. PubMed ID: 24198429
[TBL] [Abstract][Full Text] [Related]
10. Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.
Bouma P; Leavitt M; Zhang PF; Sidorov IA; Dimitrov DS; Quinnan GV
J Virol; 2003 Jul; 77(14):8061-71. PubMed ID: 12829845
[TBL] [Abstract][Full Text] [Related]
11. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
[TBL] [Abstract][Full Text] [Related]
12. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
13. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
[TBL] [Abstract][Full Text] [Related]
14. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
Sullivan N; Sun Y; Sattentau Q; Thali M; Wu D; Denisova G; Gershoni J; Robinson J; Moore J; Sodroski J
J Virol; 1998 Jun; 72(6):4694-703. PubMed ID: 9573233
[TBL] [Abstract][Full Text] [Related]
15. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
16. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
17. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
[TBL] [Abstract][Full Text] [Related]
19. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
[TBL] [Abstract][Full Text] [Related]
20. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.
McKeating JA; Thali M; Furman C; Karwowska S; Gorny MK; Cordell J; Zolla-Pazner S; Sodroski J; Weiss RA
Virology; 1992 Sep; 190(1):134-42. PubMed ID: 1382339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
